Coffee always takes a hammering in the popular press and with the hippies ( left over relics from the 60's),
but is coffee good or bad? Apparently it is a preventative for alziemers, researchers think it could be. In some trials it prevented heart disease and in others it promoted it, Michael T Murray had a good explanation for this one. In the P450 cytochrome there are enzymes that break down substances to render them harmless, some people are fast metabolisers of caffeine and others are slow. If you are a fast metaboliser you will get a cardio benefit and if you are a slow metaboliser you will receive an elevated risk. Westerners tested in Britain, USA and Australia were about 50/50 but when they tested Japanese people they found 85%, or thereabouts were fast metabolisers, and therefore would receive a huge benefit from drinking coffee.
Dr. Michael Murray
natural living
Nutrigenomics and Biochemical Individuality
Introduction
In the late 1970s when I began discovering the importance of nutrition in human health one of my major heroes was Roger Williams. This brilliant man was responsible for discovering many B vitamins including pantothenic acid and folic acid. In fact, at his laboratory at the University of Texas more vitamins and their variants were discovered than in any other laboratory in the world.
One of the concepts that Dr. Williams introduced that has proven to be one of the most provocative concepts in nutritional medicine is the idea of “biochemical individuality.” Each of us has unique biochemical traits that determine who we are and how we interact with the world around us. Biochemical individuality results from a combination of our genes and our environment – nature and nurture. These factors play a big role in determining how healthy we are and what ailments we are likely to experience.
Nowadays, the term biochemical individuality has been replaced by the term “nutrigenomics.” This term refers to the application of the study of our genetic code and the related sciences of genomics, transcriptomics, proteomics and metabolomics as they relate to human nutrition. Though nutrigenomics is the new term, the concept behind the term clearly owes its origin to Dr. Williams.
Nutrigenomics and Detoxification Reactions
One of the major determinants of our nutrigenomic profile is a family of perhaps one hundred enzymes known as the cytochrome P450 enzymes. These enzymes play a critical role in detoxifying drugs, cancer-causing compounds, and hormones. Generally, each enzyme is designed to metabolize certain types of chemicals, but there is also a lot of overlap among the P450 family. This “back-up system” ensures that your liver is usually able to detoxify your body efficiently.
Detoxification of harmful chemicals like pesticides as well as body hormones is basically a two-step process. The first step in the two-step detoxification of toxic chemicals is referred to as “Phase I detoxification.” This process involves one of three possibilities:
* An enzyme simply breaks apart the toxic molecule into two or more harmless components.
* An enzyme changes the molecule so that it can be dissolved in water. This makes it possible for the toxin to circulate in the bloodstream to the kidneys, where it can be excreted in urine.
* An enzyme can transform the toxin into another form so that phase II enzymes can then go to work on it.
In Phase II detoxification, enzymes bind other molecules to the toxins. In essence, this is like “handcuffing” the toxin so it can be escorted out of the body by the biological equivalent of security guards. The process of adding one molecule to another is called conjugation. Conjugation either neutralizes the toxin so it will do no harm if it remains in the body, or it changes the toxin to a water-soluble form so it can be excreted. In this process, the body uses six main compounds to bind to the toxins: acetyl coenzyme A (acetyl CoA); glutathione; glycine and other amino acids; glucuronic acid; methyl groups; and sulfur.
The activity of and interplay between Phase I and Phase II reactions is probably the single most important factor that determines our biochemical individuality. Differences in the P450 enzymes can explain why some people can smoke without developing lung cancer and why certain individuals are more susceptible to the harmful effects of pesticides and other toxic chemicals.
Nutrigenomics in Action
Incorporating aspects of nutrigenomics into clinical research is clarifying the health effects of dietary practices. For example, research on the effects of coffee consumption on heart disease has been equivocal – one study finds no correlation between coffee consumption and hypertension, while the next shows a correlation with heart attack risk while another shows elevated cholesterol for those drinking more than four cups, while the next shows no correlation, but only if paper filters are used. In these sorts of unclear relationships nutrigenomics can be invaluable in clarifying the picture.
A recent study supports this notion. The study examined the association between heart attack incidence.1 Unlike other studies looking into this association the researchers also measured the activity of the liver enzyme that detoxifies caffeine - cytochrome P450 1A2 (CYP1A2). When the researchers divided the group according to whether they possessed a form of this enzyme that quickly metabolizes caffeine (CYP1A2*1A) or slowly metabolized caffeine (CYP1A2*1F) suddenly the picture on the impact of caffeine intake became very clear. As can be seen from Table 1, those with the rapid caffeine breakdown actually decrease their risk of a heart attack by drinking coffee, while slow caffeine metabolizers actually dramatically increase their risk! Drinking four cups a day of coffee was associated with a 17% decrease risk in fast metabolizers and a 260% increased risk in slow metabolizers.
The CYP1A2 enzyme system accounts for nearly 15% of cytochrome P450 enzymes in the human liver and is involved in many detoxification reactions. In addition to caffeine, this enzyme detoxifies 20 commonly prescribed drugs. There are huge variations in population groups—for example about 50% of Caucasians have the slow variant compared to only 14% of Japanese.2 Researchers have found a remarkable 15-fold variation in its activity.3 The CYP1A2 system is also influenced by many drugs, hormones, and dietary factors. For example, it is inhibited by oral contraceptives and induced by cruciferous vegetables.4
Reexamining Medical Research
One of the major drawbacks in conventional medical research is that it is almost entirely based on the attempt to homogenize the study population. In other words, the research model assumes that we are all alike. What is becoming more and more clear is that if researchers do not determine the genomics of their study population, the results achieved may be compromised. The caffeine metabolism sample above is a very good example. By determining the genomics of the study meaningful results were obtained. If the study was conducted in Japan without profiling caffeine metabolism, the results would have likely shown caffeine consumption reduced heart attack rates since 84% of the Japanese population rapidly metabolize caffeine. If it was conducted on Caucasians in the U.S., they would have found no effect because the protection in fast metabolizers would have been countered by the slow metabolizers.
As I hope that you can now recognize, this study of coffee consumption, nutrigenomics, and heart attack rates is extremely provocative. Its results lead to tremendous ramifications. As my colleague, Joseph Pizzorno, N.D., recently stated in an editorial on this every issue:
“The bottom line: Current randomized clinical trial methodology is deeply flawed. Unless the study population is genetically homogenous in the relevant biochemistry—and lifestyle factors that induce CYP activity are controlled and the participant’s diet standardized—we cannot trust the results.”
My caveat to that is that through better understanding of biochemical individuality eventually we will be able to utilize natural medicine to an even greater extent. I believe truly in the prophetic statement of Thomas Edison:
"The doctor of the future will give no medicine, but will interest his patient in the care of the human frame, in diet and in the cause and prevention of disease."
References:
1. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295:1135-41.
2. Nakajima M, Yokoi T, Mizutani M, et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994;3:413-21.
3. Ikeya K, Jaiswal A K, Owens RA, et al. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Molec. Endocr. 1989;3:1399-408.
4. Vistisen K, Poulsen HE and Loft S. Foreign compound metabolism capacity in man measured from
metabolites of dietary caffeine. Carcinogenosis 1992;13:1561-8
Last year researchers found coffee may help prevent gout attacks as well---
Coffee consumption and risk of incident gout in men: a prospective study.
Choi HK, Willett W, Curhan G.
Arthritis Research Centre of Canada, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. hchoi@partners.org
OBJECTIVE: Coffee is one of the most widely consumed beverages in the world and may affect the risk of gout via various mechanisms. We prospectively evaluated the relationship between coffee intake and the risk of incident gout in a large cohort of men. METHODS: Over a 12-year period, we studied 45,869 men with no history of gout at baseline. Intake of coffee, decaffeinated coffee, tea, and total caffeine was assessed every 4 years through validated questionnaires. We used a supplementary questionnaire to ascertain whether participants met the American College of Rheumatology survey criteria for gout. RESULTS: We documented 757 confirmed incident cases of gout. Increasing coffee intake was inversely associated with the risk of gout. The multivariate relative risks (RRs) for incident gout according to coffee consumption categories (0, <1, 1-3, 4-5, and > or = 6 cups per day) were 1.00, 0.97, 0.92, 0.60 (95% confidence interval [95% CI] 0.41-0.87), and 0.41 (95% CI 0.19-0.88), respectively (P for trend = 0.009). For decaffeinated coffee, the multivariate RRs according to consumption categories (0, <1, 1-3, and > or = 4 cups per day) were 1.00, 0.83, 0.67 (95% CI 0.54-0.82), and 0.73 (95% CI 0.46-1.17), respectively (P for trend = 0.002). Total caffeine from all sources and tea intake were not associated with the risk of gout. CONCLUSION: These prospective data suggest that long-term coffee consumption is associated with a lower risk of incident gout.
PMID: 17530645 [PubMed - indexed for MEDLINE]
